GSK-VRX-RET-E22-304

Study Sponsor: GSK

Study Title

A Multicenter, Open-Label, Long-Term, Safety, Tolerability and Efficacy Study of Retigabine in Adult Epilepsy Patients With Partial-Onset Seizures (Extension of Study VRX-RET-E22-302)

Medicine or Vaccine (generic name)

retigabine, ezogabine

Sponsor Identification Number

VRX-RET-E22-304

Trial Registry Identification Number(#'s)

NCT00310388 2006-000956-42

Medical Condition

Epilepsy

Phase

Phase 3

Link to study details on the GSK Clinical Study Register

https://www.gsk-studyregister.com/en/trial-details/?id=VRX-RET-E22-304

Link to study details on ClinicalTrials.gov (if available)

http://clinicaltrials.gov/show/NCT00310388

Link to study details on EudraCT (if available)

https://www.clinicaltrialsregister.eu/ctr-search/search?query=2006-000956-42

Datasets and Documents Available for this Study

Raw dataset	Annotated case report form	Dataset specifications	Protocol with any amendments
Analysis-ready dataset	Reporting and analysis plan	Clinical study report	Ready to Share

Additional information about the data and documents available for this study

This is a follow-up study to VRX-RET-E22-302. An annotated case report form is not available for this study. A blank case report form will be provided.

Date Added to this Site

July 2017